Mycovia Pharmaceuticals, Inc. is a biotechnology company based in Durham, North Carolina, focused on developing innovative therapies for serious fungal infections. The company specializes in the research and development of novel antifungal treatments, leveraging advanced scientific methodologies to address unmet medical needs in this domain. Mycovia is committed to improving patient outcomes through its targeted approach to fungal disease management, aiming to enhance the quality of life for affected individuals.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

21 Patents

#43 in Durham, NC

#360 in North Carolina

#15,712 in US

#30,001 in the World

Durham, NC, United States of America

Mycovia Pharmaceuticals, Inc.

Forward Citations = 12

19 inventors:

William Joel Hoekstra (21 out of 81 patents)

Christopher M Yates (15 out of 46 patents)

Asaf Alimardanov (10 out of 15 patents)

4. Mark Behnke (10 out of 10 patents)

5. Scott A David (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mycovia Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/mycovia-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

6 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]